Rezolute's Ersodetug meets primary endpoint in Phase 3 tumor hyperinsulinism trial
RZLT•Rezolute said ersodetug met the primary efficacy endpoint in its Phase 3 upLIFT study in tumor hyperinsulinism. Most participants discontinued intravenous glucose; full results and statistical analysis are expected by mid-December 2026.
1. Trial results
Rezolute announced preliminary results showing ersodetug met the primary efficacy endpoint in its Phase 3 upLIFT study in tumor hyperinsulinism. Most participants discontinued intravenous glucose, and the drug was well tolerated, with no drug-related safety findings reported to date. Full results, including statistical analysis of the primary endpoint, are expected by mid-December 2026; the company plans FDA discussions in the first quarter of 2027 as it seeks approval for congenital and tumor hyperinsulinism.
